Novo Investors Jump Ship After Its Billion-Dollar Heart Drug Dies on the Operating Table (-10%)

By Stocks News   |   3 months ago   |   Stock Market News
Novo Investors Jump Ship After Its Billion-Dollar Heart Drug Dies on the Operating Table (-10%)

Alexa, play “Achey Breaky Heart” by Billy Ray Cyrus…

Novo Nordisk shareholders just got ANOTHER painful reminder that making miracle drugs is a lot harder than selling them during a CNN commercial break.

First came CagriSema, the drug that was supposed to shrink waistlines faster than Zepbound. The only thing that ended up shrinking was Novo's market cap after shares dumped 16%. 

Then just a few days ago, a judge greenlit part of a securities fraud lawsuit accusing Novo of playing a little too loose with how it described the dosing protocol in the pivotal CagriSema trial.

And now? The Ozempic maker is heading into the weekend with yet another black eye after shares sank as much as 10%.

This time, public enemy #1 was Ziltivekimab, Novo's experimental heart drug that was supposed to become the company's next big growth story beyond the obesity gold rush.

Unfortunately, biology had other plans.

The late-stage study followed more than 6,300 patients with cardiovascular disease, chronic kidney disease, and elevated inflammation to see whether the drug could reduce the risk of major cardiovascular events like heart attacks, strokes, and cardiovascular death.

It technically did what scientists hoped in one respect.

The drug successfully blocked the inflammatory pathway it was designed to target.

The tiny little problem? Patients didn't actually experience a statistically meaningful reduction in heart attacks, strokes, or cardiovascular deaths. Cue the “hello darkness, my old friend” soundbite.

Prior to today, the stock was barely breakeven for the year. Now... not so much.

Of course, in the land of Big Pharma, controlling the narrative is almost as important as it is in politics. So naturally, leadership tried putting on a brave face.

Chief Scientific Officer Martin Holst Lange immediately reached for the damage-control script, insisting the trial flop doesn't alter Novo's long-term cardiovascular strategy.

I mean… what is he supposed to say? "Yeah, we just spent years and a mountain of shareholder cash building a drug that got smoked by the placebo."

The elephant in the room is what this means for Novo's pipeline. 

Going back to 2022, investors happily valued the company like the Amazon of weight loss thanks to Ozempic and Wegovy.

Now every promise of "the next big thing" is met with the same skepticism fight fans reserve for another Conor McGregor comeback. 

Because obesity drugs aren't staying a two-horse race forever. Eli Lilly is already breathing down Novo's neck, Hims keeps throwing rocks through the pharmacy window, and a swarm of biotech startups is lining up to take their shot.

One failed Phase 3 trial isn't the end of the world.

But they're a whole lot easier to stomach when you've got another blockbuster right behind it.

As for what's next? Management may decide the fastest way to build the next Ozempic is to wire someone else a few billion dollars.

At the time of publishing this article, Stocks.News holds positions in Amazon as mentioned in the article.

Did you find this insightful?

Disclaimer: Information provided is for informational purposes only, not investment advice. We do not recommend buying or selling stocks. Stock price discussions are based on publicly available data. Readers should conduct their own research or consult a financial advisor before investing. Owners of this site have current positions in stocks mentioned throughout the site, Please Read Full Disclaimer for details Here https://app.stocks.news/page/disclaimer